PepGen Inc. (PEPG) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US7133171055
PepGen Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -93.61 m USD |
| EBIT | -93.62 m USD |
| Net income | -89.66 m USD |
| Diluted EPS – continuing operations | -2.12 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
More stocks
- Panda Dairy Corp (300898.SZ)
- InBody Co.Ltd (041830.KQ)
- TWIN DISC INC (TWIN)
- Nanjing TDH Technology Co. Ltd. A (301378.SZ)
- Axiomtek Co Ltd (3088.TWO)
- Chongqing Xishan Science&Technology Co. Ltd. A (688576.SS)
- PTG Energy PCL (PTG.BK)
- Kennede Electronics MFG Co Ltd (002723.SZ)
- Colonial Coal International Corp (CAD.V)
- Primis Financial Corp. (FRST)
- Fujian Jinsen Forestry Co Ltd (002679.SZ)
- PT Raharja Energi Cepu Tbk (RATU.JK)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.